August J. Moretti's most recent trade in Cibus Inc - Ordinary Shares - Class A was a trade of 39,301 Stock Option (Right-to-Buy) done . Disclosure was reported to the exchange on May 22, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cibus Inc - Ordinary Share... | August J. Moretti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 39,301 | 39,301 | - | - | Stock Option (Right-to-Buy) | |
| Cibus Inc - Ordinary Share... | August J. Moretti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2024 | 14,733 | 14,733 | - | - | Stock Option (Right-to-Buy) | |
| 4D Molecular Therapeutics Inc | August J. Moretti | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.41 per share. | 15 May 2023 | 3,000 | 11,045 | - | 9.4 | 28,230 | Common Stock |
| 4D Molecular Therapeutics Inc | August J. Moretti | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2023 | 3,000 | 217,060 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | August J. Moretti | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | August J. Moretti | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2022 | 3,000 | 220,060 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | August J. Moretti | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.41 per share. | 21 Dec 2022 | 3,000 | 6,595 | - | 9.4 | 28,230 | Common Stock |
| 4D Molecular Therapeutics Inc | August J. Moretti | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | August J. Moretti | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | August J. Moretti | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.41 per share. | 12 Apr 2021 | 1,000 | 2,000 | - | 9.4 | 9,410 | Common Stock |
| 4D Molecular Therapeutics Inc | August J. Moretti | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Apr 2021 | 1,000 | 223,060 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | August J. Moretti | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2021 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) |